Franz Hefti
Algemeen Directeur bij PREVAIL THERAPEUTICS INC.
Profiel
Franz F.
Hefti is the founder of Limerick BioPharma, Inc. (founded in 2004) and Cognition Therapeutics, Inc. (founded in 2007).
He is currently the Chief Executive Officer at Prevail Therapeutics, Inc. (since 2018) and holds the position of Chairman at Spinogenix, Inc., Director at Cadent Therapeutics, Inc., Director at FAAH Pharma, Inc., and Director at Sophren, Inc. He has previously held positions as President, Chief Executive Officer & Director at Acumen Pharmaceuticals, Inc., Director-Neuroscience Research Department at Genentech, Inc. (1992-1995), Director at Embera NeuroTherapeutics, Inc., Director at Annovis Bio, Inc., Independent Director at Alzheon, Inc., Director at Covagen AG, Director at Asceneuron SA, Director at Ataxion, Inc., Senior Vice President-Neuroscience Research at Merck & Co., Inc. (1995-2002), Chief Scientific Officer at Avid Radiopharmaceuticals, Inc. (2007-2010), Chief Operating Officer at Proclara Biosciences, Inc. (2017-2018), Professor at the University of Southern California, Associate Professor at the University of Miami, Executive Vice President-Drug Development at Rinat Neuroscience Corp.
(2003-2006), and Chief Development Officer & Vice President at Chlorion Pharma, Inc. He obtained a doctorate degree from the University of Zurich.
Actieve functies van Franz Hefti
| Bedrijven | Functie | Begin |
|---|---|---|
| PREVAIL THERAPEUTICS INC. | Algemeen Directeur | 01-03-2018 |
| Sophren, Inc. | Directeur/Bestuurslid | - |
Cadent Therapeutics, Inc.
 Cadent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cadent Therapeutics, Inc. develops novel small molecule therapeutics to treat schizophrenia and other cognitive disorders. It focuses on modulating synaptic plasticity, the mechanism through which the brain builds and evolves the synaptic networks that carry out cognitive functions such as learning and memory. The company was founded by Kollol Pal, Frank S. Menniti, and Bertrand Leo Chenard in 2010 and is headquartered in Cambridge, MA. | Directeur/Bestuurslid | - |
Spinogenix, Inc.
 Spinogenix, Inc. Pharmaceuticals: MajorHealth Technology Spinogenix, Inc. provides biotechnology services. It offers therapeutics, neurodegeneration, amyloids, traumatic brain injury and neurorestorative. The company was founded by Stella Sarraf in 2016 and is headquartered in San Diego, CA. | Voorzitter | - |
FAAH Pharma, Inc.
 FAAH Pharma, Inc. BiotechnologyHealth Technology FAAH Pharma, Inc. operates as a project-focused company developing a clinical asset initially for postherpetic neuralgia. The company was founded on June 26, 2014 and is headquartered in Montreal, Canada. | Directeur/Bestuurslid | 07-08-2014 |
Eerdere bekende functies van Franz Hefti
| Bedrijven | Functie | Einde |
|---|---|---|
Proclara Biosciences, Inc.
 Proclara Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Proclara Biosciences, Inc. provides treatment of chronic neurodegenerative diseases. The firm develops therapies for protein misfolding diseases, such as chronic diseases of aging and certain orphan indications by harnessing General Amyloid Interaction Motif (GAIM), which is a multi-target approach that reduces levels of pathological misfolded protein deposits. The company was founded by Hampus Jacob Hillerstrom and Jonathan Eithan Solomon in December 2006 and is headquartered in Cambridge, MA. | Algemeen Directeur | 26-04-2017 |
Avid Radiopharmaceuticals, Inc.
 Avid Radiopharmaceuticals, Inc. Medical/Nursing ServicesHealth Services Avid Radiopharmaceuticals, Inc. provides molecular imaging services. It develops new molecular imaging agents capable of changing the medical management of significant, chronic human diseases by identifying the first stages of pathological change, potentially assisting in earlier diagnosis, and better management and development of new therapies. The company was founded by Daniel M. Skovronsky in 2004 and is headquartered in Philadelphia, PA. | Hoofd Techniek/Wetenschap/O&O | 01-12-2010 |
Rinat Neuroscience Corp.
 Rinat Neuroscience Corp. BiotechnologyHealth Technology Rinat Neuroscience Corp. manufactures and markets drugs for treating neurological diseases. The company was founded by Arnon Rosenthal and Patrick G. Lynn on November 21, 2000 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01-06-2006 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01-12-2002 |
| ░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Opleiding van Franz Hefti
| University of Zurich | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 4 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| ACUMEN PHARMACEUTICALS, INC. | Health Technology |
| ANNOVIS BIO, INC. | Health Technology |
| COGNITION THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 16 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Avid Radiopharmaceuticals, Inc.
Avid Radiopharmaceuticals, Inc. Medical/Nursing ServicesHealth Services Avid Radiopharmaceuticals, Inc. provides molecular imaging services. It develops new molecular imaging agents capable of changing the medical management of significant, chronic human diseases by identifying the first stages of pathological change, potentially assisting in earlier diagnosis, and better management and development of new therapies. The company was founded by Daniel M. Skovronsky in 2004 and is headquartered in Philadelphia, PA. | Health Services |
Embera NeuroTherapeutics, Inc.
 Embera NeuroTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Embera NeuroTherapeutics, Inc. develops treatments for smoking cessation, cocaine dependence and other addictions. The company was founded by Nicholas Edward Goeders and Marie A. Lindner in 2005 and is headquartered in Sudbury, MA. | Health Technology |
Proclara Biosciences, Inc.
Proclara Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Proclara Biosciences, Inc. provides treatment of chronic neurodegenerative diseases. The firm develops therapies for protein misfolding diseases, such as chronic diseases of aging and certain orphan indications by harnessing General Amyloid Interaction Motif (GAIM), which is a multi-target approach that reduces levels of pathological misfolded protein deposits. The company was founded by Hampus Jacob Hillerstrom and Jonathan Eithan Solomon in December 2006 and is headquartered in Cambridge, MA. | Health Technology |
Alzheon, Inc.
 Alzheon, Inc. BiotechnologyHealth Technology Alzheon, Inc. engages in the provision of medical development. It specializes in treatment for brain health, memory, and aging. It offers ALZ-801, an oral small molecule inhibitor of amyloid formation and neurotoxicity with potential to be a therapy for a genetically defined population of patients with or at high risk for Alzheimer's disease and other neurodegenerative disorders. The company was founded by Martin Tolar in June 2013 and is headquartered in Framingham, MA. | Health Technology |
Rinat Neuroscience Corp.
Rinat Neuroscience Corp. BiotechnologyHealth Technology Rinat Neuroscience Corp. manufactures and markets drugs for treating neurological diseases. The company was founded by Arnon Rosenthal and Patrick G. Lynn on November 21, 2000 and is headquartered in South San Francisco, CA. | Health Technology |
Limerick BioPharma, Inc.
 Limerick BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Limerick BioPharma is dedicated to the discovery and development of novel small molecule product candidates to address areas of significant unmet medical need. Their intent is to bring forth innovative therapies that have the potential to change treatment paradigms via their enhanced safety and / or efficacy profiles. Limerick is developing novel products that can enhance the safety of existing therapeutic agents or function as innovative stand-alone therapies. Their lead programs are in the areas of metabolic diseases and solid organ transplantation. In metabolic diseases, their programs are in clinical development for treatment of diabetes and dyslipidemia. For transplant indications, their programs are in clinical development as adjunctive therapy to treat metabolic dysregulation induced by leading immunosuppressants. Beyond these first-generation programs, Limerick has developed a proprietary and cutting-edge discovery platform that can be leveraged for other high-need, high-value areas. They intend to maximize the value of their product candidates and discovery platform through independent development, licensing and other partnership opportunities. | Health Technology |
Covagen AG
 Covagen AG BiotechnologyHealth Technology Covagen AG engages in the research in as well as development, production, and distribution of pharmaceutical and diagnostic products and technologies. The company was founded by Julian Bertschinger and Dragan Grabulovski in 2007 and is headquartered in Zug, Switzerland. | Health Technology |
Cadent Therapeutics, Inc.
Cadent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cadent Therapeutics, Inc. develops novel small molecule therapeutics to treat schizophrenia and other cognitive disorders. It focuses on modulating synaptic plasticity, the mechanism through which the brain builds and evolves the synaptic networks that carry out cognitive functions such as learning and memory. The company was founded by Kollol Pal, Frank S. Menniti, and Bertrand Leo Chenard in 2010 and is headquartered in Cambridge, MA. | Health Technology |
Asceneuron SA
 Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | Health Technology |
Ataxion, Inc.
 Ataxion, Inc. BiotechnologyHealth Technology Ataxion, Inc. develops novel therapies for rare, debilitating, and underserved neurologic diseases. It focuses on orphan genetic disorders termed hereditary ataxias. It was founded by Josh Resnick and David Grayzel in April 2013 and is headquartered in Cambridge, MA. | Health Technology |
FAAH Pharma, Inc.
FAAH Pharma, Inc. BiotechnologyHealth Technology FAAH Pharma, Inc. operates as a project-focused company developing a clinical asset initially for postherpetic neuralgia. The company was founded on June 26, 2014 and is headquartered in Montreal, Canada. | Health Technology |
Spinogenix, Inc.
Spinogenix, Inc. Pharmaceuticals: MajorHealth Technology Spinogenix, Inc. provides biotechnology services. It offers therapeutics, neurodegeneration, amyloids, traumatic brain injury and neurorestorative. The company was founded by Stella Sarraf in 2016 and is headquartered in San Diego, CA. | Health Technology |
Prevail Therapeutics, Inc.
 Prevail Therapeutics, Inc. BiotechnologyHealth Technology Prevail Therapeutics, Inc. develops therapeutics for neurodegenerative diseases. The firm engages in the research and development of novel biologic gene therapies to treat Parkinson's disease and other neurodegenerative diseases. The company was founded by Asa Abeliovich on July 6, 2017 and is headquartered in New York, NY. | Health Technology |
| Sophren, Inc. | |
Chlorion Pharma, Inc.
 Chlorion Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Chlorion Pharma, Inc. Develops small molecule leads for the treatment of naturopathic pain and epilepsy. It develops therapeutics for the treatment of neuropathic pain and epilepsy. The company was founded by Jeffrey A. M. Coull, Yves De Koninck and Martin Gagnon in 2004 and is headquartered in Laval, Canada. | Commercial Services |
